FDA CRDAC: Novartis' serelaxin not ready for prime time
This article was originally published in Scrip
Advisers to the FDA were solidly unanimous in rejecting Novartis' serelaxin (RLX030), a relaxin receptor agonist, as a treatment for acute heart failure (AHF) at a 27 March meeting, which at one point got downright prickly between one of the panelists and the drug maker's key outside expert consultant, who often shares a seat on the same committee.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.